Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Despite Success of RNAi in Target Validation, OncoGenex Opts for Antisense in Cancer Program

Despite Success of RNAi in Target Validation, OncoGenex Opts for Antisense in Cancer Program

Nov 05, 2004
Premium

As a developer of antisense-based cancer treatments, OncoGenex was naturally interested in RNA interference when it came onto the scene. But despite having significant success using RNAi for target validation work, the company decided the gene-silencing technology was not quite ready for therapeutic applications, and opted for a next-generation antisense approach in its latest drug program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Mix of Human and Monkey

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

Fetal Tissue Policy Changes Expected

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

Science Papers on Approach to Isolate DNA from Sediment, Algorithm to Construct Signaling Networks

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Sequencing the Zoo

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
23
Featured Webinar

Advances in Single-Cell Proteomics: Building a Complete Picture of Cellular Identity

Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

What's Popular?

In Gene Silencing/Gene Editing

  1. CRISPR-Cas9 Genome Editing Can Lead to Extensive Chromosome Rearrangements

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.